<DOC>
	<DOCNO>NCT00538473</DOCNO>
	<brief_summary>Since influenza vaccine administer every year frequent change antigenic composition , safety immunogenicity profile GSK Biologicals ' influenza vaccine GSK576389A re-evaluated repeat vaccine administration . In study , subject previously enrol study 107973 receive dose 2007-2008 season 's formulation Fluarix GSK576389A . Only subject previously enrol study 107973 ( NCT00386113 ) eligible participation study .</brief_summary>
	<brief_title>Evaluate Safety Immunogenicity GSK Bio 's Influenza Vaccine GSK576389A After Repeated Vaccination Elderly Adults</brief_title>
	<detailed_description>This study year 3 revaccination study . Second year revaccination do study 107973 ( NCT00386113 ) . First year revaccination do study 104540 ( NCT00318058 ) . Primary study study 103304 . The Protocol Posting update order comply FDA Amendment Act , Sep 2007</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects previously vaccinate GlaxoSmithKline Biologicals Fluarixâ„¢ GSK576389A vaccines 107973 study ( NCT00386113 ) . Subjects investigator believe comply requirement protocol enrol study . A male female age &gt; = 67 year time revaccination . Written inform consent obtain subject . Free acute aggravation health status establish clinical evaluation ( medical history medical history direct examination ) enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day prior vaccination , plan use study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 21 day vaccination . Confirmed influenza infection since date previous vaccination . Planned administration influenza vaccine study vaccine entire study period . Vaccination influenza since January 2007 Northern Hemisphere 2007/2008 influenza vaccine 2006/2007 influenza vaccine . Administration 14 day immunosuppressant immunemodifying drug within six month prior administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History hypersensitivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine ( ) . Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine clinical evaluation ( medical history medical history direct physical examination ) preexist laboratory screening test . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first administration study vaccine plan administration study . Any medical condition intramuscular injection contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>67 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GSK Bio 's influenza vaccine GSK576389A</keyword>
	<keyword>Influenza Infection</keyword>
	<keyword>Fluarix</keyword>
</DOC>